Clinical trials recruiting for Melanoma (Skin)
18
Recruiting trials
10
US states with sites
8
Countries
6%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 3 |
| California | 2 |
| Florida | 1 |
| Indiana | 1 |
| Massachusetts | 1 |
| Michigan | 1 |
| North Carolina | 1 |
| Utah | 1 |
| Washington | 1 |
| West Virginia | 1 |
Top cities
Dallas, Texas 2Boston, Massachusetts 1Farmington Hills, Michigan 1Houston, Texas 1Indianapolis, Indiana 1La Jolla, California 1Morehead City, North Carolina 1Morgantown, West Virginia 1New Smyrna Beach, Florida 1Orange, California 1
Self-screener
Recruiting trials
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
- DermaSensor Postmarket Surveillance Study
- Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
- French Clinical Datbase of Melanoma Patients (RIC-Mel)
- Genomic Investigation of Unusual Responders
- High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
- Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
- Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors
- Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
- Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
- Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node
- Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
- Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma
- Rural Adult and Youth Sun Protection Study
- START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
- Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma
- Understanding the Transition from Normal Melanocytes to Nevus to Melanoma
- Versatile Ampification Single-Molecule Detection in Liquid Biopsy
Related conditions
Trials recruiting for Melanoma (Skin) often also study these conditions. Each links to its own recruiting-trial list.
Melanoma 487Non-small cell lung cancer 507Lung cancer 2180Breast cancer 2239Skin Cancer 23Melanoma Stage IV 23Melanoma Stage III 18Colorectal cancer 1359Triple-negative breast cancer 138Survivorship 12
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Melanoma (Skin) trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.